EPZ-6438

Target: This ligand targets enhancer of zeste homolog 2 (EZH2), the catalytic PRC2 methyltransferase subunit in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for enhancer of zeste homolog 2 (EZH2), the catalytic PRC2 methyltransferase subunit. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings enhancer of zeste homolog 2 (EZH2) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Degradation: EPZ-6438 can be used as a ligand component to build PROTACs that recruit an E3 ubiquitin ligase and drive selective ubiquitination of the target protein. This enables systematic evaluation of degradation efficacy, including dose–response behavior, time dependence, and dependence on proteasome activity in cellular models.

• Target Engagement Optimization: Incorporating EPZ-6438 into PROTAC architectures supports structure-guided optimization of ternary complex formation and target engagement. Researchers can compare linker lengths and attachment sites to maximize productive ubiquitination, quantify engagement using biochemical assays, and correlate engagement strength with degradation potency and recovery kinetics after washout.

• Mechanism-of-Action Studies: EPZ-6438-based PROTACs are valuable for dissecting degradation mechanisms, such as ubiquitin chain formation and trafficking-dependent effects. By combining proteasome inhibition, lysosome blockade, and ubiquitination readouts, investigators can determine whether degradation proceeds primarily via the canonical ubiquitin–proteasome pathway.

• Proteome-Wide Specificity Profiling: EPZ-6438-derived PROTACs can be applied in proteomics workflows to assess on-target specificity and off-target degradation. Quantitative mass spectrometry enables mapping of degradation signatures, identification of unintended substrates, and refinement of PROTAC design to improve selectivity while preserving robust target loss.

EPZ-6438 is a EZH2 methyltransferase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of EPZ-6438 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.